Article Details

WHO Biosimilar Guidelines Are A Tepid Attempt To Improve Access And Affordability

Retrieved on: 2022-11-12 07:17:38

Tags for this article:

Click the tags to see associated articles and topics

WHO Biosimilar Guidelines Are A Tepid Attempt To Improve Access And Affordability. View article details on hiswai:

Excerpt

Monoclonal antibodies (mABs) constitute one of the most transformative treatment regimens and have an increased dominance in the biotherapeutic ...

Article found on: healthpolicy-watch.news

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up